Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
|Videos|March 31, 2016
Dr. Sagar Lonial on Treating Patients With Smoldering Multiple Myeloma
Author(s)Sagar Lonial, MD
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses whether or not to treat patients with smoldering multiple myeloma (SMM), or asymptomatic myeloma.
Advertisement
Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses whether or not to treat patients with smoldering multiple myeloma (SMM), or asymptomatic myeloma. Lonial suggests that rather than treat SMM, oncologists should move SMM patients who may need earlier treatment into the myeloma category.
Advertisement
Related to this article
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5